HomeCompareACRX vs PLD

ACRX vs PLD: Dividend Comparison 2026

ACRX yields 232.56% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ACRX wins by $287.16M in total portfolio value
10 years
ACRX
ACRX
● Live price
232.56%
Share price
$0.86
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$293.67M
Annual income
$159,094,488.39
Full ACRX calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — ACRX vs PLD

📍 ACRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodACRXPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ACRX + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ACRX pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ACRX
Annual income on $10K today (after 15% tax)
$19,767.44/yr
After 10yr DRIP, annual income (after tax)
$135,230,315.13/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, ACRX beats the other by $130,762,344.38/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ACRX + PLD for your $10,000?

ACRX: 50%PLD: 50%
100% PLD50/50100% ACRX
Portfolio after 10yr
$150.09M
Annual income
$82,175,462.28/yr
Blended yield
54.75%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

ACRX
Analyst Ratings
10
Buy
6
Hold
1
Sell
Consensus: Buy
Altman Z
-22.3
Piotroski
4/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ACRX buys
0
PLD buys
0
No recent congressional trades found for ACRX or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricACRXPLD
Forward yield232.56%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$293.67M$6.50M
Annual income after 10y$159,094,488.39$5,256,436.18
Total dividends collected$278.92M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: ACRX vs PLD ($10,000, DRIP)

YearACRX PortfolioACRX Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$33,956$23,255.81$11,255$555.24+$22.7KACRX
2$110,134$73,800.94$13,062$1,018.59+$97.1KACRX
3$341,552$223,709.32$15,903$1,926.67+$325.6KACRX
4$1,013,853$648,391.74$20,839$3,823.32+$993.0KACRX
5$2,883,575$1,798,752.11$30,464$8,166.08+$2.85MACRX
6$7,866,701$4,781,276.29$52,054$19,457.30+$7.81MACRX
7$20,607,870$12,190,500.18$109,886$54,188.93+$20.50MACRX
8$51,895,877$29,845,455.63$304,030$186,451.18+$51.59MACRX
9$125,770,153$70,241,564.71$1,166,125$840,813.32+$124.60MACRX
10$293,668,552$159,094,488.39$6,504,190$5,256,436.18+$287.16MACRX

ACRX vs PLD: Complete Analysis 2026

ACRXStock

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.

Full ACRX Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this ACRX vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ACRX vs SCHDACRX vs JEPIACRX vs OACRX vs KOACRX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.